The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for Nezglyal (leriglitazone) as a treatment for male cALD patients, aged two to 12 years with gadolinium (Gd) negative brain lesions.   European Commission approval is expected by the end of September 2026.  […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!